Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.89 USD
Change Today +0.058 / 6.97%
Volume 140.1K
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

9530 Main Street

Clarence, NY 14031

United States

Phone: 716-270-1523

Fax: 716-877-3064

22nd Century Group, Inc. operates as a plant biotechnology company. The company focuses on tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding. Business The company is primarily involved in the following activities: the international licensing of the company’s technology, proprietary tobaccos, and trademarks; the manufacture, marketing and international distribution of RED SUN and MAGIC proprietary cigarettes; the production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); the research and development of potentially reduced-risk or modified risk tobacco products; the development of X-22, a prescription-based smoking cessation aid consisting of very low nicotine (VLN) cigarettes; and the pursuit of necessary regulatory approvals and clearances from the U.S. Food and Drug Administration (FDA) to market in the U.S X-22 as a prescription smoking cessation aid and BRAND A and BRAND B as reduced-risk or Modified Risk Cigarettes. Goodrich Tobacco Company, LLC (Goodrich Tobacco) and Hercules Pharmaceuticals, LLC (Hercules Pharmaceuticals) are subsidiaries of the company. Goodrich Tobacco is focused on commercial tobacco products and potentially reduced-risk or modified risk tobacco products. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development. The X-22 therapy protocol utilized in its sponsored Phase II-B clinical trial calls for the patient to smoke its very low nicotine (VLN) cigarettes over a six-week treatment period to facilitate the goal of the patient quitting smoking by the end of the treatment period. Goodrich Tobacco, introduced two cigarette brands, RED SUN and MAGIC, into the U.S. market in 2011. Both brands are available in regular and menthol and all brand styles are king size and packaged in hinge-lid hard packs. SPECTRUM Government Research Cigarettes The company was chosen to be a subcontractor for a government contract between RTI International (RTI) and the National Institute on Drug Abuse (NIDA) to supply altered nicotine research cigarettes (from very low to high) cigarettes to NIDA. These government research cigarettes are distributed to researchers free of charge under the mark SPECTRUM. Strategy The company’s long-term focus is the research, development, licensing, manufacturing, and worldwide sales and distribution of its products to reduce the harm caused by smoking. Intellectual Property The company controls 114 issued patents and an additional 38 patent applications; of these, the company owns 13 issued patents plus 25 patent applications and the company licenses the remaining patents and patent applications on an exclusive basis. The company’s patent coverage in the United States and China, 2 of the smoking cessation and cigarette markets worldwide, consisting of 16 issued patents and 8 pending applications and 6 issued patents and 3 pending patent applications, respectively. The company has exclusive rights to all uses of the following genes responsible for nicotine content in tobacco plants: NBB, QPT, A622, MPO and other transcription factor genes. The company owns various registered trademarks in the United States. The company also has exclusive plant variety rights in the United States (plant variety protection certificates are issued by the U.S. Department of Agriculture) and Canada. Competition In the market for FDA-approved smoking cessation aids, the company’s principal competitors are as follows: Pfizer Inc.; GlaxoSmithKline PLC; Novartis International AG; and Perrigo Company plc. Domestic competitors include Philip Morris USA; Reynolds American Inc.; Lorillard Inc.; Commonwealth Brands, Inc.; Liggett Group LCC; and Vector Tobacco Inc. Its international competitors include Philip Morris International, Inc.; Japan Tobacco Inc.; Imperial Tobacco Group plc; and other regional and local tobacco companies. The company also competes with, government-owned tobacco enterprises, such as the China National Tobacco Corporation. History 22nd Century Group, Inc. was founded in 1998.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XXII:US $0.89 USD +0.058

XXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Imperial Tobacco Group PLC 3,102 GBp -1.00
Japan Tobacco Inc ¥3,820 JPY +45.00
Lorillard Inc $68.19 USD +1.53
Perrigo Co PLC $165.97 USD +1.65
Reynolds American Inc $70.60 USD +1.80
View Industry Companies
 

Industry Analysis

XXII

Industry Average

Valuation XXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 107.5x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 94.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 22ND CENTURY GROUP INC, please visit www.xxiicentury.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.